Answer
The short excerpt you provided about BrainStorm Cell Therapeutics Inc. (ticker BCLI) only tells us that the company will hold a conference call on August 14 2025 to discuss its second‑quarter results and give a corporate update. It does not include the actual financial figures—such as the cash balance on hand, the cash‑burn rate for the quarter, or a comparison with prior periods—that are needed to answer the question directly.
Below is a step‑by‑step guide to locating and interpreting the cash‑position and burn‑rate information that companies typically disclose in a quarterly earnings release or the accompanying investor presentation:
| Where to Look | What to Expect | How to Compare |
|---|---|---|
| Full Press Release (usually posted on PR Newswire, the company’s website, or the SEC’s EDGAR system) | A “Liquidity & Capital Resources” or “Cash and Cash Equivalents” section that lists the cash balance at the end of the quarter, any cash‑raising activities (e.g., equity offerings, debt financings), and the net cash used (or generated) during the quarter. | Compare the ending cash balance to the same line from the prior quarter (Q1 2025) and the same quarter in the prior year (Q2 2024). A higher balance indicates improved liquidity; a lower balance suggests a tighter cash position. |
| Burn‑Rate Disclosure | Companies often state the net cash used in operating activities for the quarter and may also give a “cash‑burn rate” expressed as cash used per month (e.g., $X million per month). Some issuers also provide a “runway” estimate (months of cash remaining at the current burn rate). | To gauge the change, line‑up the cash‑used figure (or burn‑rate) from the current quarter with the figures from Q1 2025 and Q2 2024. A decline in cash‑used (or a lower burn‑rate) signals that the company is spending less each month, often due to cost‑containment measures, slower R&D spend, or a shift to a more capital‑efficient operating model. Conversely, an increase indicates higher spending, which could be due to expanded clinical‑trial activity, new hiring, or other growth‑related outlays. |
| Management Discussion & Analysis (MD&A) Section (in the 10‑Q filing) | Narrative explanations for why cash changed—e.g., proceeds from a recent private placement, milestone payments received, or a strategic partnership that offsets expenses. | Use the MD&A to understand drivers behind the cash‑position shift and burn‑rate change, rather than looking at raw numbers alone. For instance, a larger cash balance might be the result of a $50 million financing, while a higher burn‑rate could be tied to the launch of a Phase 2 trial. |
Typical Findings (Illustrative Example)
If the full release were available, you might see something like the following (numbers are *hypothetical** and only shown to illustrate how you would answer the question):*
| Metric | Q2 2025 | Q1 2025 | Q2 2024 |
|---|---|---|---|
| Cash & cash equivalents (end‑of‑quarter) | $115 M | $98 M | $132 M |
| Net cash used in operating activities (quarter) | $22 M | $24 M | $30 M |
| Cash‑burn rate (monthly) | $7.3 M | $8.0 M | $10.0 M |
| Estimated cash runway (months) | ~15.8 months | ~12.3 months | ~13.2 months |
Interpretation of the illustrative data
| Comparison | What it tells us |
|---|---|
| Cash balance: $115 M vs. $98 M (Q1 2025) and $132 M (Q2 2024) | The cash on hand has increased relative to the previous quarter, reflecting recent financing (e.g., a private placement) but is still lower than the same quarter a year ago, indicating that the company has drawn down some of its prior cash reserves. |
| Net cash used: $22 M vs. $24 M (Q1 2025) and $30 M (Q2 2024) | The company reduced its cash consumption compared to both the prior quarter and the prior year, suggesting tighter cost control or a slowdown in cash‑intensive activities (e.g., fewer trial enrollments). |
| Burn‑rate: $7.3 M/month vs. $8.0 M/month (Q1 2025) and $10.0 M/month (Q2 2024) | The monthly burn rate has declined substantially, extending the cash runway. This is a positive sign for liquidity, assuming the company can still fund its R&D pipeline. |
| Runway: ~15.8 months vs. ~12.3 months (Q1 2025) and ~13.2 months (Q2 2024) | The longer runway indicates the company now has more months of operating cash at the current burn rate, which can be reassuring to investors concerned about near‑term financing needs. |
How to Answer the Question with the Actual Data
- Locate the exact cash‑balance and cash‑used figures in the press release or the 10‑Q filing for Q2 2025.
- Pull the same figures for Q1 2025 and Q2 2024 (these are typically presented in a “Historical Liquidity” table).
- Calculate the month‑by‑month burn rate (cash used ÷ 3) if the company does not already provide it.
- Compare the numbers as shown in the illustrative table above, and comment on the direction (increase/decrease) and magnitude of change.
- Add context from the MD&A or the management commentary that explains why cash changed (e.g., a $50 M private placement, a partnership milestone payment, or a pause in a trial).
What to Do Next
- Visit BrainStorm Cell Therapeutics’ Investor Relations page (or the SEC’s EDGAR system) and download the Q2 2025 press release and the accompanying 10‑Q filing.
- Look for headings such as “Liquidity and Capital Resources,” “Cash and Cash Equivalents,” or “Cash Burn”.
- Extract the numbers and follow the comparison framework above to craft a precise answer.
Bottom line: The brief excerpt you posted does not contain the cash‑position or burn‑rate details needed for a direct comparison. To answer the question accurately, you’ll need to retrieve the full earnings release (or the 10‑Q) where BrainStorm Cell Therapeutics discloses its cash balance, cash used during the quarter, and any burn‑rate or runway metrics. Once you have those figures, you can compare them to the prior quarter (Q1 2025) and the same quarter a year earlier (Q2 2024) using the step‑by‑step approach outlined above.